Scientific Program
Thursday, September 7, 2023
| 18:00-19:00 |
Satellite Symposium
Hot topics in breast cancer
Supported by Baylor St. Luke’s Medical Center |
Hall A |
| Chairpersons |
Shaheenah Dawood, Dubai, UAE
Stephen Grobmyer, Abu Dhabi, UAE |
| 18:00-18:20 |
How to sequence the new strategies in metastatic TNBC
Javier Cortes, Barcelona, Spain |
18:20-19:00
18:20
18:35
18:50 |
Debate: That TAD is appropriate for those with cN2 disease at presentation
Yes: Bruce Mann, Melbourne, Australia
No: Alastair Thompson, Houston, TX, USA
Discussion |
Friday, September 8, 2023
| 09:00-09:15 |
Congress Opening |
Hall A |
| Chairpersons |
Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia |
|
Welcome from Congress chairpersons
|
| 09:15-10:20 |
Session 1: Neoadjuvant therapy |
Hall A |
| Chairpersons |
Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia |
09:15-09:45
09:15
09:25
09:35 |
Debate: That T1C HER2 positive breast cancer should have neoadjuvant therapy
Yes: Kefah Mokbel, London, UK
No: Meteb Al-Foheidi, Jeddah, Saudi Arabia
Discussion |
| 09:50-10:05 |
Management of the initially positive axilla
Stephen Grobmyer, Abu Dhabi, UAE |
| 10:05-10:20 |
Which patients with luminal cancer should be considered for neoadjuvant endocrine therapy?
Fathi Azribi, Dubai, UAE |
| 10:20-10:55 |
Coffee break, poster viewing and exhibition visit |
|
| 10:55-12:00 |
Session 2: HR+ breast cancer |
Hall A |
| Chairpersons |
Hassan Shahryar, Abu Dhabi, UAE
Sonia Otsmane, Abu Dhabi, UAE |
| 10:55-11:10 |
ER testing in breast cancer
Asif Quadri, Abu Dhabi, UAE |
| 11:10-11:20 |
Which patients with HR positive/HER2 negative should be offered CDKi’s?
Nouri Bennini, Abu Dhabi, UAE |
| 11:20-11:50 |
Update on CDK4/6 inhibitors in metastatic breast cancer
Javier Cortes, Barcelona, Spain |
| 11:50-12:00 |
What is the best option when a patient progresses on a CDK4/6 inhibitor?
Dalia Elshorbagy, Dubai, UAE |
| 12:00-13:00 Lunch break, poster viewing and exhibition visit |
| 13:00-14:15 |
Session 3: Therapy – management of low risk invasive breast cancer |
Hall A |
| Chairpersons |
Rana Irfan Mahmood, Dubai, UAE
Stephen Grobmyer, Abu Dhabi, UAE |
| 13:00-13:15 |
Use of assays
Alastair Thompson, Houston, TX, USA |
| 13:15-13:30 |
Small trial
Stuart MacIntosh, Belfast, UK |
| 13:30-13:45 |
PROSPECT
Bruce Mann, Melbourne, Australia |
| 13:45-14:15 |
Discussion
Moderator: Stephen Grobmyer, Abu Dhabi, UAE
Panelists: Alastair Thompson, Houston, TX, USA; Stuart MacIntosh, Belfast, UK; Bruce Mann, Melbourne, Australia;
Fady Geara, Abu Dhabi, UAE |
| 14:15-15:30 |
Session 4: Advanced triple negative disease |
Hall A |
| Chairpersons |
Bassim Al Bahrani, Oman
Dalia Elshorbaby, Dubai, UAE |
| 14:15-14:30 |
Novel emerging therapeutic modalities for advanced triple negative breast cancer
Shaheenah Dawood, Dubai, UAE |
14:30-15:00
14:30
14:40
14:50 |
Debate: Post immunotherapy: Is ENHERTU® the treatment of choice?
Yes: Hassan Shahryar, Abu Dhabi, UAE
No: Fathi Azribi, Dubai, UAE
Discussion |
| 15:00-15:10 |
Free Paper:
The value of early increases in cardiac troponin and natriuretic peptides for asymptomatic chemotherapy-linked cardiotoxicity detection in breast cancer patients
Saule Balmagambetova, Aktobe, Kazakhstan |
| 15:10-15:30 |
Tumour Board
|
Hall A |
| Moderator |
Javier Cortes, Barcelona, Spain |
| Panelists |
Rana Irfan Mahmood, Dubai, UAE; Sonia Otsmane, Abu Dhabi, UAE; Bassim Al Bahrani, Oman |
| 15:30-15:45 |
Coffee break, poster viewing and exhibition visit |
|
| 15:45-17:15 |
Session 5: Imaging |
Hall A |
| Chairpersons |
Aly Abdel Razek, Abu Dhabi, UAE
Khalid Saeed Balaraj, Abu Dhabi, UAE |
| 15:45-16:15 |
The role of MRI in breast cancer
Karla Sepulveda, Houston, TX, USA |
| 16:15-16:25 |
Free Paper:
Cancer diagnosis by clinical breast exam in BRCA carrier vs. intermediate to average risk women
Tehillah Menes, Ramat Gan, Israel |
| 16:25-16:35 |
Free Paper:
Shearwave elastography of the breast to characterise breast lesions
Natalie Clements, Bunbury, Australia |
16:35-17:05
16:35
16:45
16:55 |
Debate: That all patients with early breast cancer should have preoperative contrast based imaging
Yes: Bruce Mann, Melbourne, Australia
No: Stuart McIntosh, Belfast, UK
Discussion |
Saturday, September 9, 2023
| 09:00-10:00 |
Session 6: HER2 low breast cancer |
Hall A |
| Chairpersons |
Abdul Rahman El Kinge, Dubai, UAE
Nouri Bennini, Abu Dhabi, UAE |
| 09:00-09:15 |
Antibody-drug conjugates (ADCs)
Javier Cortes, Barcelona, Spain |
| 09:15-09:30 |
Challenges in reporting HER2-low breast cancer: A pathologist’s prospective
Basel Atrabulsi, Abu Dhabi, UAE |
09:30-10:00
09:30
09:40
09:50 |
Debate: In HER2 low, hormone negative metastatic breast cancer, TDXd should be preferred over sacituzumab govitecan
Yes: Mohsen Mokhtar, Cairo, Egypt
No: Abdul Rahman El Kinge, Dubai, UAE
Discussion |
| 10:00-10:20 |
Tumour Board |
Hall A |
| Moderator |
Hassan Shahryar, Abu Dhabi, UAE |
| Panelists |
Dalia Elshorbagy, Dubai, UAE; Kaltar Das, Dubai, UAE; Annett Hamadi, Dubai, UAE; Aladdin Marraoui, Abu Dhabi, UAE |
| 10:20-11:35 |
Session 7: Breast reconstruction |
Hall A |
| Chairpersons |
Archana Shetty, Dubai, UAE
Raffi Gurunian, Abu Dhabi, UAE |
| 10:20-10:45 |
Breast surgical reconstruction
Sebastian Winocour, Houston, TX, USA |
| 10:45-11:00 |
Free Paper:
Long-term patient-reported outcomes in women undergoing mastectomy with and without delayed breast reconstruction in a population-based cohort
Shelley Potter, Bristol, UK |
11:00-11:10
|
Free Paper:
Clinical and patient-reported outcomes following delayed-immediate autologous breast reconstruction after post-mastectomy radiotherapy: Are sacrificial implants good practice?
Saud Hamza, Perth, Australia |
11:10-11:35
|
Case discussion:
Approaches to breast reconstruction in a patient who requires PMRT
Moderator: Archana Shetty, Dubai, UAE
Panelists: Raffi Gurunian, Abu Dhabi, UAE; Fady Geara, Abu Dhabi, UAE; Shelly Potter, Bristol, UK; Saud Hamza, Perth, Australia |
| 11:35-11:50 |
Coffee break, poster viewing and exhibition visit |
|
| 11:50-12:50 |
Satellite Symposium:
Disruptive innovation: Harness the power of RADAR
Supported by Merit Medical |
Hall A |
| Chairperson |
Kefah Mokbel, London, UK |
| 11:50-12:20 |
Shining light on precision: Navigating non-palpable breast lesions with SCOUT® Radar Localization
Kefah Mokbel, London, UK |
| 12:20-12:50 |
Advanced applications with SCOUT® Radar Localization
Kayla Griffith, Denver, CO, USA |
| 12:50-13:00 |
Free Paper:
Indocyanine green as a practical and viable alternative to blue dye or lymphoscintigraphy in sentinel node mapping
Michael Law, Melbourne, Australia |
| 13:00-13:10 |
Free Paper:
Diagnostic accuracy of sentinel lymph node biopsy using indocyanine green compared to technetium-99 radioisotope with methylene blue dye in N0 early breast cancer: A systematic review
Naresh Kumar, Mangalagiri, India |
| 13:10-13:40 |
Lunch break, poster viewing and exhibition visit |
|
| Chairpersons |
|
|
| 13:40-14:20 |
Session 8: When is less better? |
Hall A |
| Chairpersons |
Abdul Rahman El Kinge, Dubai, UAE
Aladdin Marraoui, Abu Dhabi, UAE |
| 13:40-13:50 |
Optimising function outcomes
Alastair Thompson, Houston, TX, USA |
| 13:50-14:00 |
Optimising radiation therapy following breast conserving therapy
Fady Geara, Abu Dhabi, UAE |
| 14:00-14:10 |
De-escalation of oncoplastic surgery
Tibor Kovac, Abu Dhabi, UAE |
| 14:10-14:20 |
Molecular test to reduce chemotherapy
Fathi Azribi, Dubai, UAE |
| 14:20-14:35 |
Congress closing and Award presentation |
Hall A |
| Chairpersons |
Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia
|
